Navigation Links
OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
Date:6/24/2009

vival as the primary endpoint in patients treated with first-line docetaxel chemotherapy; the other trial design investigates pain palliation as the primary endpoint in patients treated with second-line docetaxel chemotherapy.

OGX-011 has received Fast Track designation from the FDA for the treatment of progressive metastatic prostate cancer in combination with docetaxel.

About the Special Protocol Assessment and Agreement Process

Under a Special Protocol Assessment (SPA), a company and the FDA can reach an agreement on the design and size of a clinical trial to support a regulatory submission. This agreement can be in writing and cannot be changed after the clinical trial begins except: (i) with written agreement of the company and the FDA; or (ii) if the director of the FDA reviewing division determines that "a substantial scientific issue essential to determining the safety or effectiveness of the drug" was identified after testing began.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase 2 clinical trials in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS), to effective
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
2. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
3. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
4. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
5. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
6. OncoGenex Reports First Quarter Financial Results
7. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
8. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
9. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
10. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
11. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Bethesda, MD (PRWEB) December 23, 2014 ... signed into law H.R. 83, the Omnibus and ... the first time, made hydrocephalus a condition eligible ... Research Programs (CDMRP) administered by the Department of ... conjunction with its allies on Capitol Hill, is ...
(Date:12/24/2014)... 23, 2014 Pipette.com announces their ... followers can submit their #HolidayInTheLab pictures for a chance ... mates. , For those struggling to think of a ... Holiday in the Lab Contest provides the ideal holiday ... to send pictures of their chemistree, holiday sweaters, ...
(Date:12/24/2014)... 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... Clinical Trial Application (CTA) with the United ... seeking regulatory approval to initiate clinical trials for the ... Contingent on the Company receiving CTA regulatory approval, ... to assess the safety, tolerability and dose escalation of ...
(Date:12/22/2014)... CHAPEL HILL, N.C. , Dec. 22, 2014 ... ALNE) today announced that it has signed a ... biotechnology company that has developed and patented a ... and medical diagnostics products that enable rapid on-site ... and alcohol use/abuse and health issues in an ...
Breaking Biology Technology:Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3ALNE Announces Intention To Acquire BioTechPharma 2
... NEW YORK, May 15 SPO Medical ... microprocessor technologies for,use in portable monitoring devices, announced ... 31, 2008., Gross revenues for the period ... gross revenues. The increase in revenues was mainly,attributed ...
... American Oriental,Bioengineering, Inc. (NYSE: AOB ), a ... manufacture and commercialization,of a broad range of prescription ... released the following statement regarding the earthquake in,China:, ... of China,s earthquake and we,are thankful to report ...
... /Xinhua-PRNewswire-FirstCall/ -- Huifeng Bio-,Pharmaceutical Technology, Inc. (OTC ... of plant extracts and pharmaceutical raw materials,for ... today,announced that there was no damage incurred ... Sichuan Earthquake., Immediately following the earthquake, ...
Cached Biology Technology:SPO Medical Reports First Quarter 2008 Results 2SPO Medical Reports First Quarter 2008 Results 3American Oriental Bioengineering Comments on Earthquake 2Huifeng Bio-Pharmaceutical (HFGB) Announces No Earthquake Related Damage to Facilities 2
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint ... http://photos.prnewswire.com/prnh/20130307/600769 ... than the iPhone 5S, Samsung introduces for the ... The Galaxy S5 home button presents ...
(Date:12/17/2014)... 16, 2014  Automation is fundamentally transforming the ... than at international borders. Over the past decade, ... allowed veteran travelers to self process through border ... Kiosks at an increasing number of airports, seaports, ... According to Maxine Most , Principal ...
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... in wireless physiologic monitoring, has released a new ... changing needs of preclinical toxicology researchers. M series, ... to help toxicologists collect the best possible physiologic ... studies. Adding functional endpoints to toxicology ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... of researchers from the LGC Chemical Metrology Laboratory in the ... up with a method to detect how the proportions of ... of protons and electrons but different numbers of neutrons) vary ... is to be able to use these methods to track ...
... have identified the locking mechanism that allows some neurons ... of genes that produce a critical cell-adhesion molecule involved ... The discovery -- captured with fluorescent imaging of excitatory ... studied in culture as they continued to develop -- ...
... (Nasdaq: AWRE ), a leading supplier of broadband ... first quarter ended March 31, 2009. Revenues for the ... 22% compared to $5.9 million in the same quarter last ... diluted net income per share in accordance with U.S. generally ...
Cached Biology News:Sulphur in just one hair could blow a terrorist's alibi 2Sulphur in just one hair could blow a terrorist's alibi 3Capturing the birth of a synapse 2Aware, Inc. Reports First Quarter 2009 Financial Results 2Aware, Inc. Reports First Quarter 2009 Financial Results 3Aware, Inc. Reports First Quarter 2009 Financial Results 4Aware, Inc. Reports First Quarter 2009 Financial Results 5Aware, Inc. Reports First Quarter 2009 Financial Results 6
... to Peroxiredoxin 1 Peroxiredoxin (Prx) ... mammalian members have been known to ... apoptosis. Many isoforms (about 50 proteins), ... acid sequence homology, particularly amino-terminal region ...
... Heat activated ,• Eliminates nonspecific products ... Excellent specificity allows extension through DNA ... ,• Leaves an 'A' overhang ... of GeneChoice DNA Polymerase that remains ...
... beta Synuclein Synucleins are small, soluble ... in certain tumors. The family includes three ... gamma synuclein. The alpha and beta synuclein ... where they are seen mainly in presynaptic ...
NAK/TBK1 (CT) Affinity Purified Polyclonal Antibody...
Biology Products: